Icelandic Biotech ATx Secures €26.5M to Advance Novel Dementia Treatment
Arctic Therapeutics (ATx), an Icelandic biotechnology company, has secured €26.5 million in Series A funding to accelerate the development of its innovative approach to treating dementia. The financing round, which included participation from the European Commission's EIC Fund, will support the advancement of two lead drug candidates targeting dementia and inflammatory skin conditions.
The company's pioneering approach combines genomic analysis with bioinformatics to identify and target disease-associated genes and proteins, potentially reducing the time, cost, and risks traditionally associated with drug development.
Novel Approach to Protein-Related Dementia
AT-001, the company's flagship candidate, addresses dementia caused by harmful protein accumulations in the brain's arterial walls, specifically targeting amyloid-induced angiopathy. The oral treatment is designed to disrupt and dissolve these problematic protein clusters, potentially offering a new therapeutic strategy for dementia patients.
"AT-001 offers hope for earlier intervention and even preventive use in individuals at high risk of developing dementia based on our biomarker signals," said Ívar Hákonarson, CEO and co-founder of ATx, highlighting the treatment's "transformative potential."
Clinical Development Progress
The program has already achieved a significant milestone with the European Medicines Agency (EMA) approving a clinical trial to investigate AT-001's effects on HCCAA, a rare form of familial dementia. This advancement marks a crucial step in validating the treatment's potential therapeutic benefits.
Additionally, ATx plans to initiate clinical trials for their second candidate, AT-004, initially targeting acne before expanding into other inflammatory skin conditions.
Addressing a Growing Healthcare Crisis
The investment comes at a critical time, as dementia continues to pose a significant healthcare challenge across Europe and globally. Svetoslava Georgieva, chair of the EIC Fund Board, emphasized the scale of the problem: "In Europe alone, dementia affects over 10 million people — placing immense strain on families, healthcare systems, and economies."
The funding is expected to accelerate ATx's research efforts and potentially bring these innovative treatments closer to patients. The company's approach could represent a significant advancement in addressing the growing global burden of dementia, offering hope for both prevention and treatment of this devastating condition.